People with HIV were more likely to develop fatty liver disease if they took antiretroviral treatment that contains an integrase inhibitor or tenofovir alafenamide (TAF), a German research group has found.
Non-alcoholic fatty liver disease (NAFLD) develops through accumulation of fat in the liver. People with diabetes and / or high body mass are more likely to develop fatty liver, or steatosis. One in four people in North America and Europe is estimated to have fatty liver disease but estimates of prevalence in people with HIV vary enormously.
Read the full story at infohep.
Source : infohep
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.